Market validation Leverage NCCN guideline updates and ASCO data endorsing MammaPrint to position Agendia tests as aligned with current oncologist practice and payor criteria, creating a compelling case for expanding adoption in early-stage breast cancer clinics.

Reimbursement leverage Highlight the FDA and CE clearance status of MammaPrint and the broad coverage criteria supporting use in Stage I/II, up to 5 cm tumors and up to 3 positive nodes, to target payer discussions and drive reimbursement-enabled trials or routine use.

Clinical evidence appeal Use the MINDACT trial and real-world evidence accompanying MP and BP to demonstrate prognostic and subtyping value, enabling upsell of the MP+BP suite for precise risk stratification and treatment tailoring.

Strategic partnerships Capitalize on long-standing collaborations (such as with Quantum Leap and I-SPY 2 ecosystem) to explore joint studies, neoadjuvant settings, and expanded biomarker research opportunities that broaden clinical workflows and test utilization.

Global expansion potential Promote CE marking and CLIA-certified operations to push into European markets and other regions with IVDR frameworks, while aligning messaging to diverse guideline landscapes and payer environments to grow international footprint.